Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Biliary Cancer: early-phase trial registry

3 of 10 indexed Biliary Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Biliary Cancer: 10 US clinical trials tracked, 3 recruiting.

Biliary Cancer is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 2 of these trials.

Enrollment posture brief

Registry condition biliary-cancer

OPEN 3 | RECR 30% | LATE 0 | EARLY 8 | RANK #1724 | SPON 2

Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Biliary Cancer (this)30%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Biliary Cancer

Biliary Cancer lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Biliary Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Biliary Cancer is recruiting below its size-band peers.

    3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Biliary Cancer research.

    University of Colorado, Denver accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Biliary Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Biliary Cancer research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING 400 participants

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

University of Colorado, Denver

NCT05517811

RECRUITING NA 300 participants

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

University of California, Davis

NCT06101277

RECRUITING Phase 1 60 participants

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Cancer Institute (NCI)

NCT05849480

ACTIVE NOT RECRUITING Phase 1 702 participants

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca

NCT04644068

COMPLETED Phase 1 45 participants

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

University of California, San Francisco

NCT00626158

COMPLETED Phase 2 43 participants

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Cancer Institute (NCI)

NCT00924027

COMPLETED Phase 2 42 participants

Pembrolizumab and GM-CSF in Biliary Cancer

Robin Kate Kelley

NCT02703714

COMPLETED Phase 2 39 participants

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

University of Michigan Rogel Cancer Center

NCT01661114

COMPLETED Phase 1 23 participants

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

University of Colorado, Denver

NCT00551096

COMPLETED Phase 1 22 participants

IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread

Masonic Cancer Center, University of Minnesota

NCT01099631

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 3

Named interventions

Most-linked intervention names on Biliary Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

capecitabine Drug
2 trials
Gemcitabine Drug
2 trials
Salmonella typhimurium Biological
1 trials
ZD6474 Drug
1 trials
High Dose Radiation (HDR) Brachytherapy Radiation
1 trials
PET Scan Diagnostic test
1 trials
T- Dxd Drug
1 trials
AZD5305 Drug
1 trials

US sites by state

Facility locations filed on Biliary Cancer trials. A trial with sites in several states counts in each.

California 3 trials
Maryland 2 trials
Colorado 2 trials
Utah 1 trials
Texas 1 trials
Oklahoma 1 trials
New York 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Biliary Cancer page

10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Biliary Cancer condition card totals 10 registered trials; most-linked intervention capecitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.